Cargando…

Development of Newborn Screening for Pompe Disease

Detalles Bibliográficos
Autores principales:	Hwu, Wuh-Liang, Chien, Yin-Hsiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422982/ https://www.ncbi.nlm.nih.gov/pubmed/33073004 http://dx.doi.org/10.3390/ijns6010005

Ejemplares similares

The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
por: Chiang, Shu-Chuan, et al.
Publicado: (2020)

A review of treatment of Pompe disease in infants
por: Chien, Yin-Hsiu, et al.
Publicado: (2007)

Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease
por: Chiang, Shu-Chuan, et al.
Publicado: (2018)

Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease
por: Chien, Yin-Hsiu, et al.
Publicado: (2013)

Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan
por: Chien, Yin-Hsiu, et al.
Publicado: (2022)

Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease()
por: Chien, Yin-Hsiu, et al.
Publicado: (2017)

Newborn Screening for Pompe Disease
por: Sawada, Takaaki, et al.
Publicado: (2020)

Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study
por: Peng, Steven Shinn-Forng, et al.
Publicado: (2016)

The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients
por: Feeney, Erin J, et al.
Publicado: (2014)

A pilot study shows the positive effects of continuous airway pressure for treating hypernasal speech in children with infantile-onset Pompe disease
por: Zeng, Yin-Ting, et al.
Publicado: (2021)

Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

High incidence of null variants identified from newborn screening of X-linked adrenoleukodystrophy in Taiwan
por: Chen, Hui-An, et al.
Publicado: (2022)

Newborn Screening for Pompe Disease: Pennsylvania Experience
por: Ficicioglu, Can, et al.
Publicado: (2020)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

Web-Based Newborn Screening System for Metabolic Diseases: Machine Learning Versus Clinicians
por: Chen, Wei-Hsin, et al.
Publicado: (2013)

Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests
por: Wang, Li-Yun, et al.
Publicado: (2013)

Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice
por: Lee, Ni-Chung, et al.
Publicado: (2020)

Establishing Pompe Disease Newborn Screening: The Role of Industry
por: Keutzer, Joan M.
Publicado: (2020)

Current status of newborn screening for Pompe disease in Japan
por: Sawada, Takaaki, et al.
Publicado: (2021)

A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI
por: Ames, Elizabeth G., et al.
Publicado: (2020)

The First Year Experience of Newborn Screening for Pompe Disease in California
por: Tang, Hao, et al.
Publicado: (2020)

STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021)

Lessons Learned from Pompe Disease Newborn Screening and Follow-up
por: Klug, Tracy L., et al.
Publicado: (2020)

Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants
por: Burton, Barbara K., et al.
Publicado: (2020)

Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I
por: Dorley, M. Christine, et al.
Publicado: (2023)

Precocious puberty in patients with Pompe disease
por: Tsai, Meng-Ju Melody, et al.
Publicado: (2023)

Newborn screening for pompe disease? a qualitative study exploring professional views
por: van El, Carla G, et al.
Publicado: (2014)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
por: Smith, Laurie D., et al.
Publicado: (2020)

Muscle ultrasound: A useful tool in newborn screening for infantile onset pompe disease
por: Hwang, Hsuen-En, et al.
Publicado: (2017)

Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective
por: Saich, Raymond, et al.
Publicado: (2020)

At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening
por: Lukacs, Zoltan, et al.
Publicado: (2020)

Type I Gaucher disease with exophthalmos and pulmonary arteriovenous malformation
por: Chen, Chun-An, et al.
Publicado: (2005)

Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease
por: Prosser, Lisa A., et al.
Publicado: (2018)

Heterogeneous nonataxic phenotypes of spinocerebellar ataxia in a Taiwanese population
por: Chen, Szu‐Ju, et al.
Publicado: (2019)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Curated incidence of lysosomal storage diseases from the Taiwan Biobank
por: Tsai, Meng-Ju Melody, et al.
Publicado: (2023)

Eye anomalies and neurological manifestations in patients with PAX6 mutations
por: Chien, Yin-Hsuan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_aojlqu4l5s6k0dpol4dctbggum